Pharmaceutical 3D Printing Technology Integrating Nanomaterials and Nanodevices for Precision Neurological Therapies
Pharmaceutics,
Год журнала:
2025,
Номер
17(3), С. 352 - 352
Опубликована: Март 9, 2025
Pharmaceutical
3D
printing,
combined
with
nanomaterials
and
nanodevices,
presents
a
transformative
approach
to
precision
medicine
for
treating
neurological
diseases.
This
technology
enables
the
creation
of
tailored
dosage
forms
controlled
release
profiles,
enhancing
drug
delivery
across
blood−brain
barrier
(BBB).
The
integration
nanoparticles,
such
as
poly
lactic-co-glycolic
acid
(PLGA),
chitosan,
metallic
nanomaterials,
into
3D-printed
scaffolds
improves
treatment
efficacy
by
providing
targeted
prolonged
release.
Recent
advances
have
demonstrated
potential
these
systems
in
conditions
like
Parkinson’s
disease,
epilepsy,
brain
tumors.
Moreover,
printing
allows
multi-drug
combinations
personalized
formulations
that
adapt
individual
patient
needs.
Novel
approaches,
including
stimuli-responsive
systems,
on-demand
dosing,
theragnostics,
provide
new
possibilities
real-time
monitoring
disorders.
Despite
innovations,
challenges
remain
terms
scalability,
regulatory
approval,
long-term
safety.
future
perspectives
this
suggest
its
revolutionize
treatments
offering
patient-specific
therapies,
improved
penetration,
enhanced
outcomes.
review
discusses
current
state,
applications,
nanotechnology
treatment,
highlighting
need
further
research
overcome
existing
challenges.
Язык: Английский
Dimethyl Fumarate Sterically Stabilized Solid Lipid Nanoparticles. Physicochemical properties and in vitro drug release
Ferreira da Silva Gisela Bevilacqua Rolfsen,
Daynara D. Souza,
de Souza Moraes Ariana
и другие.
International Journal of Nanomaterials Nanotechnology and Nanomedicine,
Год журнала:
2025,
Номер
11(1), С. 015 - 026
Опубликована: Янв. 1, 2025
In
this
work
Dimethyl
Fumarate
(DMF)-loaded
and
DMF-unloaded
Solid
Lipid
Nanoparticles
(SLNs)
were
developed
characterized
by
Dynamic
Light
Scattering
(DLS),
Atomic
Force
Microscopy
(AFM),
Scanning
Electron
(SEM),
Differential
Calorimetry
(DSC),
X-ray
Diffraction
(XRD).
vitro
release
assay
was
also
performed,
DMF
quantified
GC-MS.
SLNs
prepared
a
two-step
methodology
using
hot
nanoemulsification
followed
ultrasound
irradiation.
The
results
of
the
mean
diameter,
polydispersity,
zeta
potential
in
range
157
to
525
nm,
0.20
0.6,
-30
-7mV,
respectively.
with
spherical
elliptical
shapes
evidenced
AFM
SEM
techniques.
XRD
DSC
analyses
revealed
strong
interaction
among
SLN
components
significant
loss
crystallinity
set
these
structured
SLNs.
Encapsulation
efficiency
up
99%
loading
capacity
dependent
on
O/S
ratio
has
been
achieved.
could
be
analyzed
first-order
kinetics.
Язык: Английский
High-cis astaxanthin nano lipid carrier: Preparation and bioavailability analysis
Food Bioscience,
Год журнала:
2025,
Номер
unknown, С. 106780 - 106780
Опубликована: Май 1, 2025
Язык: Английский
Brain Delivery Strategies for Biomacromolecular Drugs: Intranasal Administration
International Journal of Nanomedicine,
Год журнала:
2025,
Номер
Volume 20, С. 6463 - 6487
Опубликована: Май 1, 2025
Macromolecular
Drugs
(including
monoclonal
antibodies,
recombinant
proteins,
and
nucleic
acid
therapies)
have
become
a
cornerstone
strategy
for
intervening
in
complex
pathological
mechanisms
such
as
cancer,
autoimmune
diseases,
genetic
disorders
due
to
their
high
specificity
disease
targets
low
off-target
toxicity.
However,
compared
traditional
small-molecule
drugs,
the
molecular
weight
(>10
kDa)
structural
complexity
of
macromolecular
drugs
result
extremely
transmembrane
permeability.
This
is
particularly
challenging
treatment
central
nervous
system
(CNS)
where
blood-brain
barrier
(BBB)
imposes
stringent
selectivity,
further
limiting
drug
delivery
efficiency.
review
focuses
on
breakthrough
nose-to-brain
(NtB)
delivery.
On
one
hand,
NtB
pathway
bypasses
BBB,
enabling
direct
CNS
other
nanocarrier
technology
can
synergistically
achieve
systemic
brain-targeted
transport.
Based
latest
research
advances,
this
article
systematically
examines
feasibility
delivering
via
administration.
We
comprehensively
summarize
relevant
carriers
discuss
potential
advantages
intranasal-brain
treatment.
Notably,
while
significant
progress
has
been
made
field,
exploration
still
needed
regarding
challenges
clinical
translation.
Язык: Английский